Dissemin is shutting down on January 1st, 2025

Published in

Nature Research, Nature Communications, 1(12), 2021

DOI: 10.1038/s41467-021-25167-5

Links

Tools

Export citation

Search in Google Scholar

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

Journal article published in 2021 by Donal T. Skelly, Adam C. Harding, Javier Gilbert Jaramillo, Michael L. Knight, Skelly Dt, Stephanie Longet, Anthony Brown, Senthil Chinnakannan, Timothy Donnison, Peny Zacharopoulou, Emily Adland, Mohammad Ali, Patpong Rongkard, Matthew Pace, Helen Brown and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

AbstractThe extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and other emergent variants.